Christelle Huguet
Executive VP and Head of R&D

Excellent. Thanks, everyone, for joining, and hello. I am pleased to welcome you this afternoon to our corabotase LANTIC Phase II glabellar line KOL presentation, which will also be found on ipsen.com. Please turn to Slide 2. Please take note of our forward-looking statements, which outline the routine risks and uncertainties contained within this presentation.

Please turn to Slide 3. I am delighted to be joined by Professor Kerscher today, the PI for the global Phase II LANTIC trial, who will present the aesthetic proof-of-concept data. We will both be available to take your questions at the end. I will start by introducing our first-in-class Recombinant NeuroInhibitor, corabotase.

Please turn to Slide 4. The external validation of corabotase is an important milestone for aesthetic innovation. The USAN and INN have designated corabotase as a custom-engineered Recombinant NeuroInhibitor recognizing the novelty of this first-in-class molecule. If approved, it would be the first therapy in a new botase class, reflecting a differentiated engineered molecule rather than a naturally occurring toxin. It is fully designed, engineered and manufactured in-house at Ipsen, which is critical to quality control and consistency. Built from engineered functional domains of catalytic domain A and binding domain B, every element of this structure has been deliberately optimized to increase receptor affinity, enhance uptake and improve resistance to degradation, reinforcing the scientific